ACE and hydrops fetalis: Candesartan was shown to be beneficial in patients with heart failure in the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) programme designed as three parallel, independent, integrated, randomized, double‐blind clinical trials comparing candesartan with placebo in three distinct populations of patients with New York Heart Association (NYHA) Class II–IV HF based on participants' assessment of left ventricular ejection fraction (LVEF) and history of tolerability to an angiotensin‐converting enzyme (ACE) inhibitor.9